Sorrento Therapeutics

SRNE · OTC

$0.0008+$0.0006 (+300.00%)TodayMarket closed · Oct 20, 2:53 PM ET

Prev close $0.0002

About SRNE

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 949 full-time employees. The company went IPO on 2007-01-19. The firm is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. The company is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist. The Company’s proprietary fully human G-MAB antibody library and ACEA small molecule library are the pipeline of new solutions for cancer. Its diagnostics platforms include the COVIMARK lateral flow antigen test and the VIREX platform.

Employees: 949
Headquarters: San Diego, California
Listed: Jan 19, 2007
Sector: Health Care
Industry: Biotechnology
Website: sorrentotherapeutics.com

Leadership

Sorrento Therapeutics executives
Name	Title	Since	Age
Henry Ji	—	2006	58
Dorman Followwill	—	—	59
Kim Janda	—	—	65
Jaisim Shah	—	—	63
David Lemus	—	—	60
Yue Wu	—	—	59

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Sorrento Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
Lee's Pharm	Supplier and customer	HK	0.94
Mabpharm	Supplier and customer	HK	0.80
Celularity A CELU	Supplier and customer	US	0.14
ITOCHU	Supplier and customer	JP	-0.87
ACEA Therapeutics, Inc.	Supplier and customer	US	—
Aardvark Therapeutics, Inc.	Supplier and customer	US	—
Mayo Clinic	Supplier and customer	US	—
Mount Sinai Health System, Inc.	Supplier and customer	US	—
Pulsar Therapeutics, Inc.	Supplier	US	—
Scripps Research Institute	Supplier and customer	US	—

Similar companies

Companies in the same industry as Sorrento Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.